Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4620778 | 0.84 | — | — | |
| SCHEMBL4121484 | 0.83 | KMT2A (0.36) | ERN1 | |
| SCHEMBL4120606 | 0.77 | ALOX15 (0.36) | ERN1ELANE | |
| SCHEMBL4115272 | 0.72 | BCL2 (0.36) | — | |
| SCHEMBL4122102 | 0.71 | AKR1C2 (0.35) | — | |
| SCHEMBL4428218 | 0.70 | MEN1 (0.36) | — | |
| SCHEMBL5763251 | 0.70 | CYP1A2 (0.35) | — | |
| SCHEMBL5702183 | 0.70 | GAA (0.32) | — | |
| SCHEMBL5702339 | 0.69 | HTR2A (0.30) | — | |
| SCHEMBL18855995 | 0.67 | THRA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221596-A1 | Substtituted aryl oximes | BAYER CROPSCIENCE AG (DE) | 2009-09-03 | — | — | US | disclosed |
| EP-1883622-A1 | SUBSTITUTED ARYL OXIMES | Bayer CropScience Aktiengesellschaft (DE) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007090434-A1 | SUBSTITUTED ARYL OXIMES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221596-A1 | Substtituted aryl oximes | CYP1A1, PRDX1, CYP1A2 | ERN1 961/4885ELANE 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.